pharma · Non-Hodgkin Lymphoma · Advanced Solid Tumors · ADCT
ADC Therapeutics
ADC Therapeutics SA
ADC Therapeutics is a pharma organization headquartered in Lausanne, CH. It trades on NYSE under ticker ADCT. Primary therapeutic focus areas include Non-Hodgkin Lymphoma, Advanced Solid Tumors, Relapsed or Refractory B-
Lausanne, Vaud, Switzerland, CH HQ
2011 Founded
272 Employees
Public company Type
ADCT · NYSE Ticker
Company details
- Status
- Public
- HQ
- Lausanne, Vaud, Switzerland, CH
- Founded
- 2011
- Employees
- 272
- Programs
- 30
- Drugs
- 15
- Patents
- 22
ADCT-602
Phase 2 · mab · Blasts 5 Percent or More of Bone Marrow Nucleated Cells
ADCT-602 for Blasts 5 Percent or More of Bone Marrow Nucleated Cells is a Phase 2 program (mab) at ADC Therapeutics SA with 1 ClinicalTrials.gov record(s).
Internal code 2017-0938
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ADC Therapeutics SA
- Phase
- Phase 2
- Modality
- mab
- Indication
- Blasts 5 Percent or More of Bone Marrow Nucleated Cells
- Status
- terminated
- Trials
- 1